Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Diabetes in Developing Countries
Published in: International Journal of Diabetes in Developing Countries 3/2023

25-06-2022 | Insulins | Original Article

Association of serum osteocalcin with beta cell function, insulin resistance, and glycemic parameters in south Indian type 2 diabetic subjects

Authors: Vinay Kumar, Nandakrishna Bolanthakodi, Sudha Vidyasagar, Avinash Holla, Samreen M. Sheik, Sudharshan Abhishek

Published in: International Journal of Diabetes in Developing Countries | Issue 3/2023

Login to get access

Abstract

Background

Osteocalcin (OC), also known as bone Gla (gamma-carboxyglutamic acid) protein, is a marker of bone formation. OC has effect on glucose and fat metabolism. Role of OC in type 2 diabetes mellitus (T2DM) is not well studied in Indian population. Our study aimed to see the relationship between OC and parameters of glucose metabolism in type 2 diabetes mellitus.

Methods

This cross-sectional study included 120 subjects with T2DM. In each subject, fasting insulin, serum osteocalcin (measured by ELISA), fasting plasma glucose (FPG), post prandial plasma glucose (PPG), and glycated Hb (HbA1c) were measured. HOMA 2.0 model was used to measure insulin resistance (HOMA-IR) and β-cell function (HOMA-β). Then, serum osteocalcin levels were correlated with HOMA-IR, HOMA-β, FPG, PPG, and HbA1c.

Results

Serum OC levels reduced with increase in insulin resistance (HOMA-IR) (r = −0.274, p = 0.004); however, there was no association with the beta cell function. OC had negative association with FPG (r = −0.14, p = 0.12) and PPG (r = −0.123, p = 0.18); however, it was statistically insignificant. Glycated hemoglobin (HbA1c) was significantly reduced in diabetic patients with higher OC levels (r = −0.208, p = 0.025).

Conclusion

Serum OC has significant association with insulin resistance and HbA1c in subjects with T2DM, which might suggest possible role of serum OC in glucose metabolism in T2DM.
Literature
1.
2.
Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130(3):456–69.CrossRefPubMedPubMedCentral
3.
4.
Wei J, Hanna T, Suda N, Karsenty G, Ducy P. Osteocalcin promotes β-cell proliferation during development and adulthood through Gprc6a. Diabetes. 2014;63(3):1021–31.CrossRefPubMedPubMedCentral
5.
Classification and Diagnosis of Diabetes. Diabetes Care. 2017;40(Supplement 1):S11.
6.
7.
Organization WH. Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva. 2008;8-11:2011.
8.
Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059–62.CrossRefPubMed
9.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.CrossRefPubMed
10.
Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–95.CrossRefPubMed
11.
Ferron M, McKee MD, Levine RL, Ducy P, Karsenty G. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone. 2012;50(2):568–75.CrossRefPubMed
12.
Takashi Y, Koga M, Matsuzawa Y, Saito J, Omura M, Nishikawa T. Undercarboxylated osteocalcin can predict insulin secretion ability in type 2 diabetes. J Diabetes Investig. 2017;8(4):471–4.CrossRefPubMedPubMedCentral
13.
Kanazawa I, Tanaka S, Sugimoto T. The association between osteocalcin and chronic inflammation in patients with type 2 diabetes mellitus. Calcif Tissue Int. 2018;103(6):599–605.CrossRefPubMed
14.
Sayinalp S, Gedik O, Koray Z. Increasing serum osteocalcin after glycemic control in diabetic men. Calcif Tissue Int. 1995;57(6):422–5.CrossRefPubMed
15.
Lucey AJ, Paschos GK, Thorsdottir I, Martínéz JA, Cashman KD, Kiely M. Young overweight and obese women with lower circulating osteocalcin concentrations exhibit higher insulin resistance and concentrations of C-reactive protein. Nutr Res. 2013;33(1):67–75.CrossRefPubMed
16.
Brown JP, Malaval L, Chapuy MC, Delmas PD, Edouard C, Meunier PJ. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1984;323(8386):1091–3.CrossRef
17.
Jung KY, Kim KM, Ku EJ, Kim YJ, Lee D-H, Choi SH, Jang HC, Shin CS, Park KS, Lim S. Age-and sex-specific association of circulating osteocalcin with dynamic measures of glucose homeostasis. Osteoporos Int. 2016;27(3):1021–9.CrossRefPubMed
18.
Kindblom JM, Ohlsson C, Ljunggren Ö, Karlsson MK, Tivesten AAsa, Smith U, et al. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res. 2009;24(5):785–791.
19.
Hwang Y-C, Jeong I-K, Ahn K-J, Chung H-Y. Circulating osteocalcin level is associated with improved glucose tolerance, insulin secretion and sensitivity independent of the plasma adiponectin level. Osteoporos Int. 2012;23(4):1337–42.CrossRefPubMed
20.
Sarkar PD, Choudhury AB. Relationships between serum osteocalcin levels versus blood glucose, insulin resistance and markers of systemic inflammation in central Indian type 2 diabetic patients. Eur Rev Med Pharmacol Sci. 2013;17(12):1631–5.PubMed
21.
Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, Yano S, Sugimoto T. Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int. 2011;22(1):187–94.CrossRefPubMed
22.
Zhou M, Ma X, Li H, Pan X, Tang J, Gao Y, Hou X, Lu H, Bao Y, Jia W. Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individuals. Eur J Endocrinol. 2009;161(5):723–9.CrossRefPubMed
23.
Aoki A, Muneyuki T, Yoshida M, Munakata H, Ishikawa S, Sugawara H, et al. Circulating osteocalcin is increased in early-stage diabetes. Diabetes Res Clin Pract. 2011;92(2):181–6.CrossRefPubMed
24.
Ma X, Chen F, Hong H, Lv X, Dong M, Wang Q. The relationship between serum osteocalcin concentration and glucose and lipid metabolism in patients with type 2 diabetes mellitus-the role of osteocalcin in energy metabolism. Ann Nutr Metab. 2015;66(2–3):110–6.CrossRefPubMed
25.
Iki M, Tamaki J, Fujita Y, Kouda K, Yura A, Kadowaki E, Sato Y, Moon JS, Tomioka K, Okamoto N, Kurumatani N. Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study. Osteoporos Int. 2012;23(2):761–70.CrossRefPubMed
26.
Hwang Y-C, Jee J-H, Jeong I-K, Ahn KJ, Chung HY, Lee M-K. Circulating osteocalcin level is not associated with incident type 2 diabetes in middle-aged male subjects: mean 8.4-year retrospective follow-up study. Diabetes Care. 2012;35(9):1919–24.CrossRefPubMedPubMedCentral
27.
Weiler HA, Lowe J, Krahn J, Leslie WD. Osteocalcin and vitamin D status are inversely associated with homeostatic model assessment of insulin resistance in Canadian Aboriginal and white women: the First Nations Bone Health Study. J Nutr Biochem. 2013;24(2):412–8.CrossRefPubMed
28.
Kanazawa I, Yamaguchi T, Tada Y, Yamauchi M, Yano S, Sugimoto T. Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. Bone. 2011;48(4):720–5.CrossRefPubMed
29.
Wang Q, Zhang B, Xu Y, Xu H, Zhang N. The relationship between serum osteocalcin concentration and glucose metabolism in patients with type 2 diabetes mellitus. Int J Endocrinol. 2013;2013:1–7.
Metadata
Title
Association of serum osteocalcin with beta cell function, insulin resistance, and glycemic parameters in south Indian type 2 diabetic subjects
Authors
Vinay Kumar
Nandakrishna Bolanthakodi
Sudha Vidyasagar
Avinash Holla
Samreen M. Sheik
Sudharshan Abhishek
Publication date
25-06-2022
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 3/2023
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-022-01087-y

Other articles of this Issue 3/2023

International Journal of Diabetes in Developing Countries 3/2023 Go to the issue

Original Article

Diabetic retinopathy: long-term follow-up of Ecuadorian patients with type 2 diabetes in primary care

Original Article

Improvement of biochemical and hematological parameters in alloxan-induced diabetic rats via administration of ethanol extract of Garcinia kola seeds

Original Article

Follow-up frequency impacts metabolic control in diabetes patients under MMC framework—a retrospective study

Original Article

Insulin antibody as a biomarker to monitor the development of type 2 diabetes in county hospitals in China

Original Article

Could the PON1 phenotype play a key role in insulin resistance?

Original Article

Serum glucose, a cost-effective alternate of plasma glucose in diagnosing and monitoring diabetes mellitus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits